Filter News
Area of Research
- (-) Biology and Environment (12)
- (-) Neutron Science (8)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (3)
- Clean Energy (32)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (3)
- Isotopes (2)
- Materials (21)
- Materials for Computing (4)
- National Security (10)
- Sensors and Controls (1)
- Supercomputing (23)
News Topics
- (-) Artificial Intelligence (4)
- (-) Biomedical (10)
- (-) Machine Learning (2)
- (-) Microscopy (4)
- (-) Security (2)
- (-) Sustainable Energy (7)
- 3-D Printing/Advanced Manufacturing (11)
- Advanced Reactors (3)
- Big Data (2)
- Bioenergy (12)
- Biology (18)
- Biotechnology (5)
- Buildings (2)
- Chemical Sciences (8)
- Climate Change (8)
- Composites (3)
- Computer Science (12)
- Coronavirus (10)
- Critical Materials (1)
- Cybersecurity (1)
- Decarbonization (4)
- Energy Storage (7)
- Environment (16)
- Frontier (1)
- Fusion (2)
- Grid (1)
- High-Performance Computing (6)
- Isotopes (4)
- Materials (15)
- Materials Science (17)
- Molten Salt (1)
- Nanotechnology (11)
- National Security (2)
- Net Zero (1)
- Neutron Science (40)
- Nuclear Energy (9)
- Partnerships (5)
- Physics (8)
- Polymers (1)
- Quantum Science (4)
- Simulation (4)
- Space Exploration (3)
- Summit (7)
- Transformational Challenge Reactor (2)
- Transportation (4)
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.